Archive

May 16, 2025

Browsing

European equity markets, initially poised for a subdued start on Friday, found upward momentum as the trading session commenced, buoyed by a rally in healthcare shares and renewed optimism surrounding US-China trade relations.

Investors, however, remained watchful, balancing the positive sentiment with ongoing global trade tensions and awaiting key regional economic data.

In premarket indications, Euro Stoxx 50 and Stoxx 600 futures had hinted at a flat to slightly positive open. Yet, as trading got underway, European shares extended their gains.

The pan-European STOXX 600 index advanced 0.4% by 0710 GMT, positioning itself for a fifth consecutive weekly rise.

This positive trajectory was mirrored across other local bourses, with Germany’s DAX notably trading near record high levels.

The heavyweight healthcare sub-index was a significant driver, climbing 1.4%, propelled by strong performances from pharmaceutical giants Novo Nordisk and Novartis.

The improved risk appetite was largely attributed to benign headlines suggesting a temporary truce in US-China trade disputes.

EU’s confident stance and key economic releases

The intricate dance of international trade remains a central theme for market participants.

European Union officials reiterated on Thursday that the bloc is actively pursuing a more comprehensive tariff reduction agreement with the United States, one that goes beyond the scope of current negotiations with the UK and China.

EU negotiators have expressed confidence in the bloc’s economic leverage, signaling a firm stance against being pressured into unfavorable terms.

On the economic data front, investor attention is keenly focused on the upcoming release of the Eurozone trade balance figures for March.

Additionally, Italy’s latest inflation rate and France’s unemployment data are anticipated, which could provide further insights into the region’s economic health.

With a light schedule for major corporate earnings, these macroeconomic developments and evolving trade narratives are expected to be primary drivers of market sentiment.

ECB navigates inflation

Adding another layer to the market calculus, commentary from European Central Bank officials suggests a potential nearing of the peak in its interest rate cycle.

Governing Council member Martins Kazaks told CNBC that the ECB’s interest rates are “relatively close to the terminal rate” if inflation continues to track within the central bank’s expectations.

“Currently, if one takes a look at the dynamics of inflation, we are by and large within the baseline scenario and if the baseline scenario holds, then I think we are relatively close to the terminal rate already,” stated Kazaks, who also serves as the Latvian central bank governor, speaking to CNBC’s Silvia Amaro on ‘Europe Early Edition’.

The terminal rate signifies the point at which interest rates neither hinder nor overly stimulate economic growth, allowing the central bank to achieve its inflation target.

The ECB’s key deposit facility rate currently stands at 2.25%, following a unanimous decision by the governing council to implement a 25 basis point reduction in April.

Kazaks also indicated that market expectations for a further 25 basis point cut at the ECB’s next policy meeting on June 5 are “relatively appropriate, in my view..

This view aligns with remarks made by fellow ECB board member Isabel Schnabel last week, who said: “The appropriate course of action is to keep rates close to where they are today – that is, firmly in neutral territory.”

While investment banks offer slightly varied outlooks, with Goldman Sachs anticipating two rate cuts this year and JPMorgan forecasting one, the overarching sentiment from within the ECB points towards a cautious approach as it navigates the path towards its inflation goals.

The post Europe markets open: STOXX 600 rises 0.4% on trade hopes, ECB signals rate peak appeared first on Invezz

The US Department of the Interior announced on Monday (May 12) that it will fast track environmental permitting for Anfield Energy’s (TSXV:AEC,OTCQB:ANLDF) Velvet-Wood uranium project in Utah

The decision slashes what would typically be a years-long review process down to just 14 days, and makes Velvet-Wood the first uranium project to be expedited under a January 20 statement from President Donald Trump. In it, he declares a national energy emergency and emphasizes the importance of restoring American energy independence.

This week’s decision signals what Anfield calls “a decisive shift in federal support for domestic nuclear fuel supply.”

The Velvet-Wood project, located in San Juan County, Utah, is expected to produce uranium used for both civilian nuclear energy and defense applications, as well as vanadium, a strategic metal used in batteries and high-strength alloys.

Secretary of the Interior Doug Burgum characterized the move as part of an urgent federal response to what he said is “an alarming energy emergency” created by the “climate extremist policies” of the previous administration.

“President Trump and his administration are responding with speed and strength to solve this crisis,” he said. “The expedited mining project review represents exactly the kind of decisive action we need to secure our energy future.”

Anfield acquired Velvet-Wood, which is currently on care and maintenance, from Uranium One in 2015.

The asset sits on the site of a previously active operation. Between 1979 and 1984, Atlas Minerals extracted approximately 400,000 metric tons of ore from the Velvet deposit, recovering around 4,000,000 pounds of U3O8. If approved, the revived project would disturb only three acres of new surface area, according to the interior department.

‘As a past-producing uranium and vanadium mine with a small environmental footprint, Velvet-Wood is well- suited for this accelerated review,’ said Anfield CEO Corey Dias.

He added that the company aims ‘to play a meaningful role in rebuilding America’s domestic uranium and vanadium supply chain and reducing reliance on imports from Russia and China.”

The company also owns the Shootaring Canyon uranium mill in Utah, which it plans to restart. The facility, described as one of only three licensed, permitted and constructed conventional uranium mills in the country, would convert uranium ore into uranium concentrate bound for nuclear fuel production.

Uranium market sentiment turning a corner?

After a rocky start to 2025, the uranium market is showing signs of renewed strength and resilience.

According to Sprott Asset Management’s latest uranium report, the U3O8 spot price rose by 5.4 percent in April, climbing to US$67.70 per pound from a March low of US$63.20. The price recovery continued into early May, with the spot price briefly touching US$70, a nearly 10 percent gain from 2025 lows.

This rebound has renewed investor confidence and appears to signal the beginning of a steadier climb, underpinned by tight supply conditions, resurgent utility activity and greater clarity around US trade and tariff policy.

The uranium term price, which remains steady at US$80, continues to reflect strong long-term fundamentals. This persistent premium over spot pricing has re-energized the uranium carry trade — where traders purchase spot uranium for future delivery under term contracts — helping to support spot prices and inject fresh liquidity into the market.

A major contributor to the uranium market’s renewed confidence has been improved policy visibility in the US.

The Trump administration’s decision to pause the implementation of its new reciprocal tariffs for 90 days provided utilities with the breathing room needed to resume contracting.

Although uranium was excluded from the initial tariff package, it remains part of an ongoing Section 232 investigation into critical minerals, a move that Sprott believes elevates uranium’s strategic profile.

As for the long-term outlook, uranium’s bullish case is also being bolstered by growing power demands from artificial intelligence and data centers. In April, Google (NASDAQ:GOOGL) announced funding for three new nuclear projects, each with at least 600 megawatts of planned capacity.

These moves align with a broader US Department of Energy strategy that includes identifying 16 federal sites for co-locating data centers and new energy infrastructure.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

Keep reading…Show less
This post appeared first on investingnews.com

Netflix said Wednesday its cheaper, ad-supported tier now has 94 million monthly active users — an increase of more than 20 million since its last public tally in November.

The company and its peers have been increasingly leaning on advertising to boost the profitability of their streaming products. Netflix first introduced the ad-supported plan in November 2022.

Netflix’s ad-supported plan costs $7.99 per month, a steep discount from its least-expensive ad-free plan, at $17.99 per month.

“When you compare us to our competitors, attention starts higher and ends much higher,” Netflix president of advertising Amy Reinhard said in a statement. “Even more impressive, members pay as much attention to mid-roll ads as they do to the shows and movies themselves.”

Netflix also said its cheapest tier reaches more 18- to 34-year-olds than any U.S. broadcast or cable network.

This post appeared first on NBC NEWS

The Trump administration is backing away from the Centers for Disease Control and Prevention (CDC) recommendations to vaccinate children and pregnant women against COVID-19, according to a new report.

The Department of Health and Human Services (HHS), led by Secretary Robert F. Kennedy, Jr., is planning to pull federal recommendations that these groups get the COVID vaccine as a routine measure, The Wall Street Journal reported Thursday.

The CDC currently recommends that everyone aged 6 months and older get vaccinated, but that guidance may be scrapped in the coming days.

It’s unclear whether HHS plans to drop the recommendation entirely or simply stop pushing it for everyone across the board, the report said.

The move would be a major shift in federal health policy and would mark a break from the blanket-vaccine approach that dominated the early years of the pandemic.

Few parents and expectant mothers have followed through with recent COVID boosters. As of April, CDC data shows just 13% of children and 14% of pregnant women had received the latest shot.

The change comes as the FDA, under Commissioner Dr. Marty Makary, prepares to roll out a tougher approval process for vaccines. 

Speaking Thursday at a gathering of food and drug lawyers, Makary said, ‘We want to see vaccines that are available for high-risk individuals, and at the same time, we want some good science. We want some good clinical data.’

Kennedy has long been critical of mRNA vaccines and mass vaccination campaigns. As HHS secretary, he now has the authority to revise CDC guidance. 

The Trump administration said it plans to drop routine COVID vaccination guidance for kids and pregnant women, marking a major shift in federal health policy, the WSJ reported.

The expected shift would undercut one of the most promoted health policies of the first Trump administration, Operation Warp Speed, and raise questions about whether insurers will continue covering the shots.

Critics of the move told the Journal it could discourage vaccination and leave immunocompromised people more vulnerable. Supporters say it brings policy back in line with science and common sense.

Both HHS and CDC did not immediately respond to Fox News Digital’s request for comment.

This post appeared first on FOX NEWS